{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:49Z","timestamp":1787009029440,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005869","name":"University of Fribourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005869","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["FNS-407240_177381"],"award-info":[{"award-number":["FNS-407240_177381"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Laboratoire Europ\u00e9en Associ\u00e9 INSERM"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefiderocol is among the latest generation of commercialized antibiotics against a large variety of MDR Gram-negative bacteria including carbapenem-resistant Enterobacterales and non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii. Cefiderocol susceptibility testing, a key element for implementing rapidly a cefiderocol-based treatment, might be still challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop a rapid culture-based test, Rapid Cefiderocol NP test, for the identification of cefiderocol resistance among MDR Enterobacterales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Rapid Cefiderocol NP test is based on glucose metabolization when bacterial growth occurs and the detection of bacterial growth in the presence of cefiderocol at 64\u2005mg\/L using iron-depleted CAMHB. Bacterial growth is visually detectable by a red-to-yellow colour change of red phenol, a pH indicator. A total of 74 clinical enterobacterial isolates from various clinical sources and of worldwide origin, among which 42 isolates were cefiderocol resistant, were used to evaluate the test performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The sensitivity and specificity of the test were found to be 98% and 91%, respectively, by comparison with the reference broth microdilution (BMD) method. All positive results were obtained within 3\u2005h after incubation at 35\u00b0C\u200a\u00b1\u200a2\u00b0C, that is a gain of time of ca. 18\u2005h (1\u2005day) compared with currently used techniques for susceptibility testing (BMD method).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This novel test is rapid, highly sensitive, specific, easily interpretable, and easy to implement in routine microbiology laboratories. Such a test may rapidly and accurately provide the information needed for the implementation of adequate cefiderocol-based treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkac340","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T16:38:54Z","timestamp":1663519134000},"page":"3456-3461","source":"Crossref","is-referenced-by-count":9,"title":["Rapid cefiderocol NP test for detection of cefiderocol susceptibility\/resistance in Enterobacterales"],"prefix":"10.1093","volume":"77","author":[{"given":"Patrice","family":"Nordmann","sequence":"first","affiliation":[{"name":"Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg , Switzerland"},{"name":"Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg , Switzerland"},{"name":"INSERM European Unit (IAME), University of Fribourg , Fribourg , Switzerland"},{"name":"Institute for Microbiology, University of Lausanne and University Hospital Centre , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bouvier","sequence":"additional","affiliation":[{"name":"Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg , Switzerland"},{"name":"Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-5286","authenticated-orcid":false,"given":"Laurent","family":"Poirel","sequence":"additional","affiliation":[{"name":"Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg , Switzerland"},{"name":"Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg , Switzerland"},{"name":"INSERM European Unit (IAME), University of Fribourg , Fribourg , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-3862","authenticated-orcid":false,"given":"Mustafa","family":"Sadek","sequence":"additional","affiliation":[{"name":"Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg , Fribourg , Switzerland"},{"name":"Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University , Qena , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"2022112816492949200_dkac340-B1","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022112816492949200_dkac340-B2","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816492949200_dkac340-B3","author":"EMA","year":"2020"},{"key":"2022112816492949200_dkac340-B4","author":"FDA","year":"2019"},{"key":"2022112816492949200_dkac340-B5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-non-susceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816492949200_dkac340-B6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2022112816492949200_dkac340-B7","doi-asserted-by":"crossref","first-page":"e0267021","DOI":"10.1128\/spectrum.02670-21","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2022112816492949200_dkac340-B8","doi-asserted-by":"crossref","first-page":"e0087721","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816492949200_dkac340-B9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/mdr.2021.0095","article-title":"Defining baseline mechanisms of cefiderocol resistance in the Enterobacterales","volume":"28","author":"Simner","year":"2022","journal-title":"Microb Drug Resist"},{"key":"2022112816492949200_dkac340-B10","doi-asserted-by":"crossref","first-page":"e0003922","DOI":"10.1128\/aac.00039-22","article-title":"Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to cefiderocol and newly developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"66","author":"Poirel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816492949200_dkac340-B11","doi-asserted-by":"crossref","first-page":"e00198-20","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816492949200_dkac340-B12","doi-asserted-by":"crossref","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022112816492949200_dkac340-B13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","article-title":"Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants","volume":"41","author":"Poirel","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022112816492949200_dkac340-B14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/microorganisms9020282","article-title":"Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study","volume":"9","author":"Bleibtreu","year":"2021","journal-title":"Microorganisms"},{"key":"2022112816492949200_dkac340-B15","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2022112816492949200_dkac340-B16","author":"EUCAST","year":"2021"},{"key":"2022112816492949200_dkac340-B17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth","volume":"94","author":"Hackel","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022112816492949200_dkac340-B18","author":"EUCAST","year":"2022"},{"key":"2022112816492949200_dkac340-B19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s10096-020-03884-x","article-title":"Rapid Polymyxin\/Pseudomonas NP test for rapid detection of polymyxin susceptibility\/resistance in Pseudomonas aeruginosa","volume":"39","author":"Sadek","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022112816492949200_dkac340-B20","article-title":"NitroSpeed-Carba NP test for rapid detection and differentiation between different classes of carbapenemases in Enterobacterales","volume":"58","author":"Nordmann","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2022112816492949200_dkac340-B21","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: the Achilles\u2019 heel of the Trojan Horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"2022112816492949200_dkac340-B22","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/ofid\/ofab466.288","article-title":"86. Access to antimicrobial susceptibility testing for novel gram-negative antibiotics","volume":"8","author":"Lee","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3456\/47369447\/dkac340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3456\/47369447\/dkac340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T11:50:52Z","timestamp":1669636252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/12\/3456\/6759843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,10,13]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac340","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,13]]}}}